Robotic mobility and humanoid technology company Human in Motion Robotics has received regulatory approval to market and sell the XoMotion exoskeleton in Canada.

It is claimed to be the first advanced medical exoskeleton with self-balancing and hands-free capabilities available in the country.

This technology is said to transform rehabilitation for patients with stroke, spinal cord injuries and other neurological conditions.

XoMotion can replicate natural human movements, offering inherent operation for patients and therapists.

It is designed to alleviate the physical demands on therapists during rehabilitation sessions by providing lifting, mobilising, assisting and training support to patients, thereby enhancing the efficiency and safety of rehabilitation programmes.

The features of XoMotion include self-balancing for stability and safety, hands-free operation for natural movement, omnidirectional functionality for complex tasks, versatility for various conditions and stages of injury, and increased safety by reducing the therapists' physical burden.

Human in Motion Robotics CEO Siamak Arzanpour said: “With XoMotion, we are setting a new standard in rehabilitation technology. Our exoskeleton not only empowers patients by facilitating natural and functional movement but also supports therapists by reducing the physical demands of their work.

“Gaining regulatory approval from Health Canada is a crucial step towards our goal of global accessibility, and we are committed to continuing this progress in other key markets.”

Human in Motion Robotics has also secured its Medical Devices Establishment License, enabling the marketing and sale of XoMotion in Canada.

The company is now setting its sights on obtaining clearance in other key markets, including the US, Asia, and the European Union (EU).

XoMotion is currently available for acquisition by rehabilitation and research facilities in Canada and is also accessible to global scientific investigators who conduct robotics research.